Tacrolimus and mycophenolate mofetil regimens in transplantation: Benefits and pitfalls

Gaetano Ciancio*, George W. Burke, David Roth, Joshua Miller

*Corresponding author for this work

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Immunosuppression, although necessary to enable the graft to escape the consequences of immune surveillance, carries some risks for the patient. There is an associated increase in neoplasms, opportunistic infections and end-organ toxicity. In addition, even with excellent patient compliance, rejection (acute and chronic) remains a major limitation that contributes to the loss or decrease in the function of the allograft. New drugs have been added to the armamentarium of immunosuppressive agents to suppress allograft rejection and to rescue grafts from cyclosporin-resistant rejection. With the availability of these immunosuppressive agents, it has become increasingly difficult to choose the appropriate combination of immunosuppressants with a beneficial effect for the patient and for the allograft. We describe 2 new immunosuppressive agents and some of their different uses in solid organ transplantation.

Original languageEnglish (US)
Pages (from-to)395-407
Number of pages13
JournalBioDrugs
Volume11
Issue number6
DOIs
StatePublished - Jun 30 1999

ASJC Scopus subject areas

  • Biotechnology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Tacrolimus and mycophenolate mofetil regimens in transplantation: Benefits and pitfalls'. Together they form a unique fingerprint.

  • Cite this